We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

EKF Diagnostics

Manufactures analysers for the measurement of glucose, lactate, hemoglobin, hematocrit and HbA1c for GP surgeries, ph... read more Featured Products: More products

Download Mobile App





EKF Diagnostics Showcases Advanced Point-of-Care and Connectivity Technologies

By LabMedica International staff writers
Posted on 17 Nov 2025

Clinical laboratories and near‑patient providers need rapid, reliable measurement of hemoglobin, HbA1c, glucose, and lactate, alongside secure device connectivity to support timely decisions. More...

EKF Diagnostics is showcasing point‑of‑care (POC) and integration technologies addressing these needs at MEDICA 2025 in Düsseldorf, Germany.

At Hall 3, Booth B69, EKF is presenting a portfolio spanning handheld and desktop analyzers and connectivity software for clinical and near‑patient use. The lineup includes the DiaSpect Tm handheld hemoglobin analyzer, which is ideal for use in any blood screening setting, even in challenging climatic and remote environments. DiaSpect Tm’s proven technology provides laboratory-quality results in just one second and transfers the test result data via Bluetooth or wired connection to EKF Link in real time.

Also being showcased is Hemo Control, a POC hemoglobin analyzer with hematocrit estimation designed to deliver fast, reliable results across a wide range of healthcare settings. Hemo Control uses the most established photometric azide methemoglobin method, ensuring reliable results with a high precision (CV <2%). It is used in blood banks, hospitals, and doctors’ offices for routine POC anemia screening.

For diabetes care, EKF is featuring the Biosen C‑Line for glucose and lactate measurement in laboratories, sports medicine, and diabetes clinics. Biosen uses special chip-sensor technology to deliver rapid, high-accuracy results at a low cost per test. The long lifespan of the sensor chip keeps maintenance to a minimum, while features such as the color touchscreen and large memory further enhance the analyzer’s user-friendliness. The Biosen series of glucose analyzers includes two models: the Biosen C-Line Clinic and the Biosen C-Line GP+.

Also on display is the Quo-Test fully automated desktop analyzer that provides easy and reliable HbA1c measurement for the monitoring and management of diabetes in a point-of-care setting. The Quo-Test HbA1c system uses patented boronate affinity fluorescence quenching technology to measure glycated hemoglobin from just 4 μl of capillary or venous whole blood. Sample results are available within four minutes and are dual-reported in IFCC and DCCT standard units, with Mono S and JDS reporting also available.

Complementing the analyzers is EKF Link, a powerful middleware solution that centralizes data management for POC analyzers on a single platform. This flexible, open data-management solution integrates seamlessly with most vendors’ POC devices, allowing real-time management of patient test results, quality control (QC) data, operator management, and analyzer configuration. Its adaptability and ease of use make EKF Link a valuable connectivity solution for hospitals, laboratories, blood banks, pharmacies, and general practitioners (GPs).

Related Links:

EKF Diagnostics
 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
New
Portable POCT Blood Gas Analyzer
BD100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.